Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 5
2001 8
2002 10
2003 15
2004 11
2005 6
2006 7
2007 10
2008 3
2009 10
2010 7
2011 7
2012 7
2013 6
2014 2
2015 1
2016 3
2017 2
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Arzoxifene as therapy for endometrial cancer.
Burke TW, Walker CL. Burke TW, et al. Gynecol Oncol. 2003 Aug;90(2 Pt 2):S40-6. doi: 10.1016/s0090-8258(03)00343-3. Gynecol Oncol. 2003. PMID: 12928005 Review.
OBJECTIVE: Arzoxifene, an orally active third-generation selective estrogen-receptor modulator (SERM), opposes the action of estrogen on the breast and endometrium but exerts an estrogen-agonist effect on bone and the lipid profile. Since this is an appealing combination f …
OBJECTIVE: Arzoxifene, an orally active third-generation selective estrogen-receptor modulator (SERM), opposes the action of estrogen …
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
Kendler DL, Palacios S, Cox DA, Stock J, Alam J, Dowsett SA, Zanchetta J. Kendler DL, et al. Osteoporos Int. 2012 Mar;23(3):1091-101. doi: 10.1007/s00198-011-1587-0. Epub 2011 Mar 4. Osteoporos Int. 2012. PMID: 21374068 Clinical Trial.
Arzoxifene increased bone mineral density and decreased bone turnover to a significantly greater extent than raloxifene. The hot flush incidence was lower with arzoxifene than raloxifene. INTRODUCTION: To assess the effect of arzoxifene versus raloxifene on c …
Arzoxifene increased bone mineral density and decreased bone turnover to a significantly greater extent than raloxifene. The hot flus …
Arzoxifene: the development and clinical outcome of an ideal SERM.
Munster PN. Munster PN. Expert Opin Investig Drugs. 2006 Mar;15(3):317-26. doi: 10.1517/13543784.15.3.317. Expert Opin Investig Drugs. 2006. PMID: 16503767 Review.
The ideal SERM would have antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. The SERM, arzoxifene (LY-353381.HCl) meets all of these criteria. This review summarises the development, preclinical studies and th …
The ideal SERM would have antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. The SERM, …
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. Cummings SR, et al. J Bone Miner Res. 2011 Feb;26(2):397-404. doi: 10.1002/jbmr.191. Epub 2010 Jul 23. J Bone Miner Res. 2011. PMID: 20658564 Free article. Clinical Trial.
Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. ...Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of veno …
Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than curren …
Arzoxifene Eli Lilly.
Marchisano-Karpman C, DeGregorio MW. Marchisano-Karpman C, et al. IDrugs. 2003 Sep;6(9):880-5. IDrugs. 2003. PMID: 12964068 Review.
Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer....
Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co …
Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
Downs RW Jr, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K. Downs RW Jr, et al. Osteoporos Int. 2010 Jul;21(7):1215-26. doi: 10.1007/s00198-009-1060-5. Epub 2009 Oct 2. Osteoporos Int. 2010. PMID: 19798460 Clinical Trial.
Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene. ...CONCLUSIONS: Arzoxifene suppressed bone turnover and increased BMD. Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to th …
Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene. ...CONCLUSIONS: Arzoxifene suppressed bone …
Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.
Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J, Michalides R. Zwart W, et al. Mol Endocrinol. 2009 Sep;23(9):1335-45. doi: 10.1210/me.2008-0268. Epub 2009 May 28. Mol Endocrinol. 2009. PMID: 19477949 Free PMC article.
In this study, we show that overexpression of a regular component of the ERalpha transcription factor complex, cyclin D1, which occurs in approximately 40% of breast cancer patients, renders cells resistant to the new promising antiestrogen, arzoxifene. Overexpression of c …
In this study, we show that overexpression of a regular component of the ERalpha transcription factor complex, cyclin D1, which occurs in ap …
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR, Bhattoa HP, Neven P, Cox DA, Dowsett SA, Alam J, Sipos A, Muram D. Goldstein SR, et al. Menopause. 2012 Jan;19(1):41-7. doi: 10.1097/gme.0b013e318223bbf4. Menopause. 2012. PMID: 21993078 Clinical Trial.
OBJECTIVE: The aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the selective estrogen receptor modulator (SERM), arzoxifene. METHODS: A predefined objective of the trial was to evaluate the effects of arzoxi …
OBJECTIVE: The aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the selective …
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Deshmane V, et al. J Clin Oncol. 2007 Nov 1;25(31):4967-73. doi: 10.1200/JCO.2006.09.5992. J Clin Oncol. 2007. PMID: 17971595 Clinical Trial.
PURPOSE: To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer. ...Adverse events were similar between the treatments, except for nausea (more frequent with arzoxifene) and vaginal discharge (more freq …
PURPOSE: To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer. ...A …
115 results